Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat.com 3 Undervalued Names Too Cheap to IgnoreAuthor: Nathan Reiff. Posted: 3/7/2026. 
Summary - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with value metrics that are historically low or competitive relative to peers or the broader market. They also offer added benefits, including compelling dividends or promising new product developments. While true value opportunities can be harder to find when many promising companies have already regained investor attention — and while some apparent value names show deteriorating operations or other red flags — well-established, stable companies can still present interesting value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Is Elon about to trigger another 315X opportunity?
Elon gave Tesla investors the chance to make more than 315 times their money when he revived the electric vehicle industry. $1 billion fund manager Louis Navellier believes Elon's "Project Apex" will mint a new generation of millionaires. Click here to get the details. Although shares have climbed more than 28% over the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45 — well below the medical-industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings rise by nearly 10% next year and has about 5% upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received approval for subcutaneous injection from the European Commission in late 2025 and reached roughly $8.4 billion in sales in Q4 2025 — an increase of nearly 7% year over year. Keytruda also shows promise in ovarian cancer trials, potentially expanding its patient base. These trends should help Merck build revenue as it prepares for Keytruda's patent expiration in 2028. Merck's portfolio is broadening as well: the company recently announced phase 3 trial results for clesrovimab-cfor (branded Enflonsia), an RSV treatment for young children. At the same time, Merck is reorganizing its human health business into two units to better expand non–cancer-drug sales as it plans for Keytruda's eventual loss of exclusivity. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Campbell's (NASDAQ: CPB) shares have fallen about 37% over the past year as the food-and-beverage staple contends with tariffs and inflation. In Q1 fiscal 2026 (ended Nov. 2, 2025), the company reported modest year-over-year declines in organic net sales and consumption, while adjusted earnings per share fell about 13%. The company has not yet seen meaningful margin improvement despite cost-saving initiatives. The near term is likely to remain challenging, and fiscal-year guidance is cautious overall. That said, an improving supply chain and strong brand loyalty — especially for premium offerings — should help protect the business. Shifts in the tariff landscape could also ease some of the external pressure. Importantly for income-focused investors, Campbell's offers a compelling dividend yield of 5.9%, though its payout ratio is relatively high at over 80%. Campbell's P/E ratio of 13.5 is the lowest in roughly four years, which may lead some investors to view the stock as an attractive value opportunity despite Wall Street caution. A Recent US Foods Rally May Continue, and Bottom-Line Growth Remains in Place Foodservice distributor US Foods (NYSE: USFD) has followed a nearly opposite path to Campbell's — shares have risen about 33% over the last year. Its P/E ratio, at 31.6, remains within a reasonable range given recent performance and expectations. On the fundamentals, US Foods is making progress: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of about 11% year over year. Better inventory management and cost-of-goods improvements are helping the company gain traction. With a $4 billion capital deployment plan in place, US Foods is positioned to sustain revenue momentum and continue growing adjusted EBITDA. Analysts rate USFD a Moderate Buy (11 Buys, 2 Holds) and see roughly 15% upside potential.
| 
